To thrive beyond rare disease, cell and gene therapy developers must scale-up manufacturing and commercialisation.

Published on January 6, 2026, in Volume 2 of the Immunity & Inflammation journal, the review begins by underscoring Professor Taniguchi's ...

Johnson & Johnson announces positive results from phase 3 MajesTEC-9 study of Tecvayli in patients with multiple myeloma: Raritan, New Jersey Friday, January 16, 2026, 10:00 Hrs [ ...

ImmunityBio, Inc. is upgraded to Buy reflecting improving Anktiva data & potential label expansions in NMIBC and NSCLC. Read ...